Skin Therapy Letter HOME
Written for dermatologists by dermatologists. Indexed by the US National Library of Medicine.
Skin Information
NETWORK
Skin Therapy Letter About STL Subscribe Today SkinCareGuide Network Site Map
CUSTOM DERMATOLOGY SEARCH:
Loading

Update on Drugs and Drug News - Number 5 1997


Class Name/Company Approval Dates and Comments

Anti-acne

Tretinoin gel 0.1%
Retin-A Micro®
Ortho

Approved by the FDA for acne treatment. Reported to cause less irritation than the original Retin-A® formulation.

Anti-HIV

Delavirdine
Rescriptor®
Pharmacia & Upjohn

Approved by the FDA April 7, 1997 as an added potency enhancement agent of HIV drug cocktails. It is a nonnucleoside reverse transcriptase inhibitor, which is not as powerful as protease inhibitors. Skin reaction is the main side effect of delavirdine.

Nelfinavir
Viracept®
Agouron Pharmaceuticals

Indication(s): Approved by the FDA March 14, 1997 for treatment of HIV infection when therapy is warranted Nelfinavir is the first protease inhibitor approved simultaneously for adults and children. In trials, it was combined with zidovudine (Retrovir®) or lamivudine (Epivir®).

Antipsoriasis

Calcipotriene ointment
Dovonex®
Bristol Myers Squibb

The efficacy claim for once daily dosing of plaque psoriasis was approved by the FDA March 20, 1997.

Antiviral

Valacyclovir tablet
Valtrex®
Glaxo Wellcome

Labelling amendment approved FDA April 30, 1997. The contraindication in immunocompromised patients has been removed and reference to “in immunocompetent adults” has been removed from the indication statements.

Laser system

Pulsed Er:Yag laser system
Derma 20®
Esc Medical Systems Ltd.

Approved by the FDA April 15, 1997. This laser system is used for general dermatologic applications, including skin resurfacing applications.

Skin Substitute

Human skin equivalent
Apligraf®
Novartis

Approved in Canada April 1997 for use in healing venous leg ulcers. See article on page one of this issue.

Wart removal

Podofilox gel 0.5%
Condylox®
Oclassen

Approved by the FDA March 13, 1997 for the treatment of perianal warts and external genital warts. The topical solution was previously approved for external genital warts only.


In this issue:

  1. Human Skin Equivalent, Apligraf — Cellular technology benefits wound repair
  2. Current Approaches to the Management of Post Herpetic Neuralgia: Part 2 — Non-Systemic
  3. Update on Sunscreens
  4. Update on Drugs and Drug News - Number 5 1997